AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02885168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Continuous administration of phenylephrine with electric syringe with increasing dosing levels: 0.0; 0.02; 0.05; 0.1; 0.2; 0.5; 0.75; 1.00; 1.50; 3.00; 4.50; 6.00; 9.00 et 12 µg/kg/min. Each level is maintained for 5 minutes. Administration of phenylephrine is stopped progressively with the same schema.~Arterial tension through an invasive approach is measured during the test.
Study NCT02885168 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: Analysis of inflammation and cellular adhesion markers and free radicals
Study NCT02885168 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Analysis of inflammation and cellular adhesion markers and free radicals
Study NCT03400982 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Bone densitometry measurement
Description: Bone densitometry and measurement of body composition
Study NCT02658097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg Pembrolizumab by IV infusion
Study NCT02658097 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single Fraction Radiation Therapy
Description: 8Gy radiation therapy will be given in a single fraction on the first day of treatment
Study NCT02859818 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: therapeutic education program
Study NCT03143491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment
Description: 1 mL of SOR007 applied topically to the ectocervix once-weekly for four weeks.
Study NCT03631355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: One gram of intravenous tranexamic acid will be administered before tourniquet inflation and 1 gram of IV TXA before closure of the incision.
Study NCT02352584 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC3110A(Quadrivalent)
Description: GC3110A(Quadrivalent), 0.5ml, intramuscular, a single dosing at Day 1
Study NCT02352584 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GC Flu(Trivalent)
Description: GC Flu Pre-filled Syringe Inj.(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1
Study NCT02352584 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GC3110A(Trivalent)
Description: GC3110A(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1
Study NCT02533791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV)
Description: one dose, 4×10\^10vp/1ml per dose
Study NCT02533791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)
Description: two doses, 0.8×10\^11vp/1ml per dose, with one dose to each arm at the same time
Study NCT04016051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin Syrup (187.5 mg)
Description: Clarithromycin Syrup 3.75 ml (187.5 mg).
Study NCT04016051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin Syrup (250 mg)
Description: Clarithromycin Syrup 5 ml (250 mg).
Study NCT02367014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elamipretide (low dose)
Description: elamipretide (0.01 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
Study NCT02536339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
Study NCT02367014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elamipretide (intermediate dose)
Description: elamipretide (0.10 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
Study NCT02367014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elamipretide (high dose)
Description: elamipretide (0.25 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
Study NCT02533791 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02367014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days
Study NCT01182168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)
Description: Patients will receive gemcitabine IV and cisplatin IV on days 1 and 8. Everolimus orally will be administered continuously (one cycle = 21 days). Everolimus will be escalated at the following dose levels: 5mg every-other-day, 5mg daily, and 10mg daily. Patients will receive a total of 6 cycles of gemcitabine and cisplatin in combination with Everolimus unless disease progression or unacceptable toxicity occurs.
Study NCT04554485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults
Study NCT03373474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local distribution points association
Description: Participants will receive acupuncture treatments using the local points set plus the local-addition points set (local distribution association) described below. Warming acupuncture will be applied at HT2, LI11, and TE9 if permitted.~Local points set: TE5, LI11, TE9, HT3, TE13, and Xiajiquan on the affected arm. Local-addition points set: LU5, PC3, SI7, TE4, TE3, HT2, TE10, LI15, and 2 other points according to the symptom on the affected arm.
Study NCT02536339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive trastuzumab at a dose of 6 milligrams per kilogram (mg/kg) of body weight once weekly via IV infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
Study NCT04604847 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood test
Description: blood test to explore BDNF level
Study NCT03295526 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph nodes debulking surgery.
Description: Radical hysterectomy and selective enlarged lymph node dissection
Study NCT00468000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixmyelocel-T
Description: IM injection
Study NCT00468000 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IM Injection
Study NCT03780712 — intervention group
Intervention type: OTHER
Intervention: Non applicable
Description: No intervention as it is an observational study
Study NCT02037984 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13®
Description: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 µg each), and 6B (4.4 µg) in each 0.5 mL dose.
Study NCT02037984 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 1x:1x:1x
Description: V114 1x:1x:1x contains 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 4.0 μg of polysaccharide serotype 6B; and 125 µg of Aluminum Phosphate Adjuvant (APA).
Study NCT02037984 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 2x:2x:2x
Description: V114 2x:2x:2x contains 4.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 8.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
Study NCT02037984 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 2x:1x:2x
Description: V114 2x:1x:2x contains 4.0 μg of polysaccharide serotypes 6A, 18C, 19A, 19F, and 23F; 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 7F, 9V, 14, 22F, and 33F; 8.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
Study NCT02027337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mcg ethinylestradiol /3 mg drospirenone
Description: One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
Study NCT02027337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mcg ethinylestradiol/3 mg drospirenone and Selmevit
Description: One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
Study NCT02027337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mcg ethinylestradiol/3 mg drospirenone
Description: One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12
Study NCT02027337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mcg ethinylestradiol/3 mg drospirenone and Selmevit
Description: One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12 Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
Study NCT02027337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 35 mcg ethinylestradiol/2 mg cyproterone
Description: 1 contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
Study NCT02027337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
Description: One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
Study NCT02573779 — intervention group
Intervention type: OTHER
Intervention: Observational - no intervention
Description: This study will observe cohorts of infants who are fed primarily either their own mother's milk or donor milk as part of their routine care. No direct intervention is performed as part of the study.
Study NCT01945580 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prolapse Repair
Description: Transvaginal anterior/apical pelvic organ prolapse repair
Study NCT00958724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Study NCT00958724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Study NCT03291171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPlan 2.0
Description: MyPlan 2.0 consists of five sessions. During these five sessions the following behaviour change techniques are used to motivate users to be more physically active or to sit less: exploring risk perceptions and perceived benefits, exploring social support, providing feedback, action planning, coping planning and monitoring.
Study NCT02717377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Study NCT02717377 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical activity
Study NCT01768247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCG (human chorionic gonadotropin)
Description: 150 international units (IU) of HCG for seven days subcutaneously concomitantly with estrogens in preparation endometrium cycles fro frozen embryos replacement
Study NCT01141777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Spirulina platensis
Description: Subjects received 19g daily of supplement averagely.This was supplied as powder daily, in packs that lasted for 2weeks each. Each subject was therefore seen every two week to obtain new stock of supplements and evaluate compliance
Study NCT01141777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soya bean
Description: Each subject received 19g of supplement on average daily. Subjects were seen every two weeks to evaluate compliance and obtain a new stock.
Study NCT00833079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% manufactured by Taro
Description: Treatment applied as a thin layer to target area twice daily for 14 days
Study NCT02037984 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 1x:1x:2x
Description: V114 1x:1x:2x contains 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 4.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
Study NCT02037984 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 0.5x:0.5x:2x
Description: V114 0.5x:0.5x:2x contains 1.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 2.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
Study NCT00833079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protopic - Tacrolimus 0.1%
Description: Treatment applied as a thin layer to target area twice daily for 14 days
Study NCT00833079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tacrolimus Vehicle manufactured by Taro
Description: Treatment applied as a thin layer to target area twice daily for 14 days
Study NCT02255578 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Endobarrier treatment in PCOS
Description: the effect of an EndoBarrier device on fertility and metabolic parameters in obese insulin resistant (IR) PCOS women
Study NCT02255578 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: clomiphene citrate treatment
Study NCT03654430 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Echocardiography
Description: Two echocardiographies will be performed in healthy newborns: The first between day 2 and day 5 of life, the second between day 60 and day 90 of life
Study NCT00476801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: German manufactured UVA1 light emitting device
Description: The UVA1 dose will be up to 130 J/cm2.
Study NCT03838328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid will be delivered by loading dose plus maintenance infusion until the end of the operation.
Study NCT03373474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local-distal points association
Description: Participants will receive acupuncture treatments using the local points set plus the distal points set (local-distal association) described below. Warming acupuncture will be applied similarly to the local distribution group, with the addition of Ren6, Ren9, bilateral SP9, and LI11 on the unaffected arm.~Local points set: TE5, LI11, TE9, HT3, TE13, and Xiajiquan on the affected arm. Distal points set: TE5, LI11, HT3, TE13 on the unaffected arm; CV4, CV6, CV9, CV12, bilateral SP6 and SP9.
Study NCT03056547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induced dyspnea
Description: Biological samples will be assessed during and after breathing discomfort induced by laboratory models of dyspnea (work/effort, air hunger).
Study NCT03229057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCP + Metformin
Description: This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
Study NCT03229057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OCP + Placebo
Description: This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
Study NCT03229057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin + Placebo
Description: This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
Study NCT03185208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: See lithium carbonate arm
Study NCT03838328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic acid will be delivered by loading dose plus maintenance infusion until the end of the operation.
Study NCT04668989 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stenfilcon A - (Test lens)
Description: Subjects will be randomized to wear test lenses for one week.
Study NCT04668989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stenfilcon A - (Test lens)
Description: Subjects will be randomized to wear test lenses for one week.
Study NCT04668989 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: kalifilcon A - (Control Lens)
Description: Subjects will be randomized to wear control lenses for one week.
Study NCT04668989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kalifilcon A - (Control Lens)
Description: Subjects will be randomized to wear control lenses for one week.
Study NCT00999401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapacitabine and seliciclib
Description: sequential or concomitant administration of sapacitabine and seliciclib
Study NCT04882020 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cortisol, BDNF, s100B, IL-1B, IL-6, IL-10, TNF-alpha
Description: compare both groups and evaluate the severity of obstructive sleep apnea modulates serum levels of inflammatory and neurocognitive markers in elederly.
Study NCT01080196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RENEW
Description: RENEW will occur on a recumbent ergometer that appears like a normal stepper ergometer. While resisting the foot pedal movement the participant experiences eccentric muscle contractions about the knee and hip while performing negative work. The progression of the 3 x/week (every other day), 12 week RENEW program will be determined as a function of the rating of perceived exertion (RPE) using a target workload on the monitor. RENEW will be increased very slowly over the first 3 weeks and, subsequently, to maintain an 11-13 perceived exertion. During the formal RENEW training regimen the participants become fully acclimated to the device (week 3-4) the total RENEW load will increase weekly with no increase in their RPE.
Study NCT02438462 — intervention group
Intervention type: OTHER
Intervention: Soluble Fibrin
Description: Calculating the area under the ROC curve of the Soluble Fibrin assay for the diagnosis of PE before evaluating the diagnostic performance of the assay.
Study NCT03908281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasted Exercise
Description: Exercise training will take place 3 times per week and will progress to 60 minutes at a workload corresponding to 80% of Ventilatory Threshold.
Study NCT03908281 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Postprandial Exercise
Description: Exercise training will take place 3 times per week and will progress to 60 minutes at a workload corresponding to 80% of Ventilatory Threshold.
Study NCT00189176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrathiomolybdate
Study NCT01914367 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cervarix
Description: 3 doses will be given, one on Day 0, one on Day 30 and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm
Study NCT01914367 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil
Description: 3 doses will be given, one on Day 0, one on Day 60 ± 2 days and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm
Study NCT03185208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: See placebo arm
Study NCT03908736 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Zinc Picolinate 15 Mg
Description: zinc picolinate, 15 mg/day for 6 months
Study NCT02379624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pectin
Description: Pectin, a representative diety fibre, is a gelatinous substance derived from the cell walls of fruits and some plants and contains galacturonan, consisting of mostly long-chain D-galacturonic acids combined into units by α-1,4 linkages. As a kind of soluble dietary fiber, pectin has been proved of controlling glucose and blood lipids. It slows rapid infusion of the liquid meal into the gut by delaying gastric emptying.
Study NCT01649921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon-gamma, Recombinant
Description: Interferon-gamma (Immukine, Boehringer-Ingelheim, Alkmaar, the Netherlands), 100mcg subcutaneously, on days 0-2-4-7-9-11. Interferon-gamma treatment will be initiated when the noradrenalin dose is reduced to 50% of maximum dose, ensuring that the sepsis-induced pro-inflammatory phase has passed